WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year the company has been included in the Index for its outstanding sustainability performance.
上海，2024年7月10日 /PRNewswire/--全球领先的合同研究、开发和制造组织（CRDMO）无锡生物制剂（“无锡生物”）（2269.HK）宣布再次被命名为富时社会责任指数系列的成分公司。这标志着该公司连续第四年因其出色的可持续发展表现而被列入该指数。
Launched in 2001 by the global index and data provider FTSE Russell, which is wholly owned by the London Stock Exchange Group, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating good sustainability practices. Inclusion in the FTSE4Good Index Series is based on independent analysis of data from over 8,000 securities in 47 developed and emerging countries. Over the past years, WuXi Biologics has realized substantial improvements in its overall FTSE Russell ESG score, as well as its theme scores. The company's ESG score in 2024 achieved the top 7% in its industry.
FTSE4Good指数系列由伦敦证券交易所集团全资拥有的全球指数和数据提供商富时罗素于2001年推出，旨在衡量表现出良好可持续发展实践的公司的业绩。FTSE4Good指数系列的纳入是基于对47个发达国家和新兴国家的8,000多只证券的数据的独立分析。在过去的几年中，药明生物在富时罗素ESG的整体评分和主题分数方面都取得了实质性的提高。该公司在2024年的ESG得分达到了该行业的前7％。
Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are very proud to be acknowledged again by FTSE Russell as a constituent of the FTSE4Good Index Series. It underscores our firm commitment to sustainability, demonstrating the success of our comprehensive ESG strategy and our effective implementation of ESG approaches. Moving forward, we will continue to regard sustainability as the cornerstone of business growth, delivering consistently strong performance for the common good of the global community."
药明生物首席执行官兼ESG委员会主席Chris Chen博士评论说：“我们很自豪再次被富时罗素认可为富时社会责任指数系列的成分股。它凸显了我们对可持续发展的坚定承诺，表明了我们全面的ESG战略的成功以及我们对ESG方法的有效实施。展望未来，我们将继续将可持续发展视为业务增长的基石，为全球社会的共同利益提供持续的强劲业绩。”
In line with the United Nations Sustainable Development Goals, WuXi Biologics has been making steady progress in pursuing sustainable development, which has been recognized by major ESG rating agencies. In the past year, the company was added to the S&P Dow Jones Sustainability World Index and Emerging Markets Index; granted a "AAA" rating from MSCI ESG Ratings; awarded the distinguished Platinum Medal by EcoVadis; recognized as an Industry and Regional Top-Rated Company by Sustainalytics; named to the CDP Water Security "A list"; and awarded an "A-" CDP Climate Change score.
根据联合国可持续发展目标，药明生物在追求可持续发展方面取得了稳步进展，这得到了主要ESG评级机构的认可。在过去的一年中，该公司被列入标普道琼斯可持续发展世界指数和新兴市场指数；获得摩根士丹利资本国际ESG评级的 “AAA” 评级；被EcoVadis授予杰出铂金奖章；被Sustainalytics评为行业和地区顶级公司；入选CDP水安全 “A级名单”；并授予CDP气候变化分数 “A-”。
About WuXi Biologics
关于药明生物
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
WuXi Biologics（股票代码：2269.HK）是一家领先的全球合同研究、开发和制造组织（CRDMO），提供端到端的解决方案，使合作伙伴能够发现、开发和制造生物制剂，从概念到商业化，造福全球患者。
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing.
WuXi Biologics在中国、美国、爱尔兰、德国和新加坡拥有超过12,000名熟练员工，利用其技术和专业知识为客户提供高效且具有成本效益的生物制剂发现、开发和制造解决方案。截至2023年12月31日，药明生物为698个综合客户项目提供支持，其中包括24个商业制造项目。
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
药明生物将环境、社会和治理（ESG）责任视为我们精神和业务战略不可分割的组成部分，我们的目标是成为生物制剂CRDMO领域的ESG领导者。我们的设施使用下一代生物制造技术和清洁能源。我们还成立了一个由首席执行官领导的ESG委员会，负责指导全面的ESG战略及其实施，增强我们对可持续发展的承诺。
For more information about WuXi Biologics, please visit: .
如需了解有关药明生物的更多信息，请访问：。
SOURCE WuXi Biologics
来源 WuXi Biologics